The addition of vaniprevir (MK-7009) to pegylated-interferon and ribavirin (PR) had a similar health-related quality of life (HRQOL) profile compared to PR alone in non-cirrhotic and cirrhotic chronic hepatitis C (CHC) patients with a prior PR failure

被引：0
|
作者：
Arduino, Jean Marie [1 ]
Shire, Norah J. [1 ]
Mast, T. Christopher [1 ]
Zhou, Amy [1 ]
Hwang, Peggy [1 ]
Mobashery, Niloufar [1 ]
机构：
[1] Merck Sharp & Dohme Corp, N Wales, PA USA
来源：
HEPATOLOGY | 2013年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
2225
引用
收藏
页码：1284A / 1284A
页数：1
相关论文
共 2 条
  • [1] Health-related quality of life (HRQOL) is not negatively impacted by therapy of MK-5172/MK-8742 during treatment of genotype (GT) 1 chronic hepatitis C in contrast to pegylated-interferon (IFN) or ribavirin (RBV)-containing therapy
    Arduino, Jean Marie
    Zhang, Boan
    Nwankwo, Chizoba
    Khawaja, Shazia
    Shaughnessy, Melissa
    Gendrano, Isaias N.
    Hwang, Peggy
    Robertson, Michael
    Mobashery, Niloufar
    Haber, Barbara A.
    HEPATOLOGY, 2014, 60 : 897A - 898A
  • [2] ASSESSING THE IMPACT OF PEGYLATED-INTERFERON/RIBAVIRIN THERAPY DURATION VERSUS VIRAL RESPONSE ON HEALTH-RELATED QUALITY OF LIFE (QOL) OUTCOMES IN CHRONIC HEPATITIS C VIRUS (HCV) PATIENTS, USING MULTIVARIATE MIXED-EFFECTS MODELING
    Thilakarathne, P.
    Van Sanden, S.
    Diels, J.
    Mehnert, A.
    VALUE IN HEALTH, 2015, 18 (03) : A242 - A243
1